Odronextamab
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: ordspono, REGN1979
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Odronextamab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2024. DrugCentral lists 2 molecular targets, including CD3E|CD3G|CD3D and MS4A1. Recorded indications include Relapsed or refractory follicular lymphoma and Relapsed or refractory large B-cell lymphoma.
- Molecular targets: CD3E|CD3G|CD3D and MS4A1 (2 listed in DrugCentral).
- Indications: Relapsed or refractory follicular lymphoma and Relapsed or refractory large B-cell lymphoma.
- ATC code: L01FX34 (Other monoclonal antibodies and antibody drug conjugates).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory large B-cell lymphoma
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| T-cell surface glycoprotein CD3 | CD3E|CD3G|CD3D | other | — |
| B-lymphocyte antigen CD20 | MS4A1 | other | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2024-08-22 | EMA | — | Regeneron Ireland Designated Activity Company (DAC) | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FX34 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Odronextamab used for?
DrugCentral lists the following indications for Odronextamab: Relapsed or refractory follicular lymphoma and Relapsed or refractory large B-cell lymphoma.
How does Odronextamab work?
Its molecular targets in DrugCentral include CD3E|CD3G|CD3D and MS4A1.
When was Odronextamab first approved?
Odronextamab was first approved by the EMA in 2024.
Browse: all drugs starting with O · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5833 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4298084 — compound record and bioactivity
- DrugBank DB16684 — drug record
- FDA UNII 8R5CM46UIO — substance identity
- UniProt P11836 (MS4A1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.